Interquim: Active Pharmaceutical Ingredients - APIs
Over 40 years manufacturing and commercializing to the highest international standards
Ferrer researches, develops, manufactures and commercializes active pharmaceutical ingredients for the pharmaceutical industry under the brand name of Interquim.
Our business is based on developing highly competitive processes for the manufacture of high added-value active pharmaceutical ingredients that meet the strictest quality specifications.
Through our growing international presence, our products are exported to the largest regulated pharmaceutical markets.
What we offer our clients:
Some of Interquim's most trusted APIs:
ROFLUMILAST
Roflumilast is an active pharmaceutical ingredient indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
PALIPERIDONE PALMITATE STERILE
Paliperidone palmitate is an active pharmaceutical ingredient that acts as an Antipsychotic
ARIPIPRAZOLE MONOHYDRATE STERILE
Aripiprazole monohydrate is an active pharmaceutical ingredient that acts as an Antipsychotic
TAPINAROF
Tapinarof is an active pharmaceutical ingredient for the treatment of Psoriasis and Atopic Dermatitis
FERRIC CARBOXYMALTOSE
Ferric carboxymaltose is an active pharmaceutical ingredient indicated for the treatment of Iron Deficiency Anemia
RIVASTIGMINE
Rivastigmine is an active pharmaceutical ingredient indicated for the treatment of Alzheimer’s Dementia
ARIPIPRAZOLE LAUROXIL
Aripiprazole lauroxil is an active pharmaceutical ingredient that acts as an Antipsychotic
LUMATEPERONE TOSYLATE
Lumateperone tosylate is an active pharmaceutical ingredient that acts as an Antipsychotic
Our APIs:
Antiarthritic
CAS No: [169590-429-5]
Status: Fully developed
Batch size: 470 Kg
Shelf life: 5 years
DMF/CEP availability: USDMF/CEP
Pharmacopeia: USP/EP
Antifungal
CAS No: [29342-05-0]
Status: Fully developed
Batch size: 170 Kg
Shelf life: 5 years
DMF/CEP availability: USDMF
Antifungal
CAS No: [41621-49-2]
Status: Fully developed
Batch size: 211 Kg
Shelf life: 5 years
DMF/CEP availability: CEP
Pharmacopeia: EP
Treatment of basal cell carcinoma and genital warts
CAS No: [99011-02-6]
Status: Fully developed
Batch size: 21 Kg
Shelf life: 5 years
DMF/CEP availability: USDMF/ASMF
Pharmacopeia: USP
Treatment of Dry Eye Syndrome
CAS No: [1025967-78-5]
Status: Fully developed
Batch size: 7.7 Kg
Shelf life: 3 years
DMF/CEP availability: USDMF
Antihypertensive
CAS No: [144689-63-4]
Status: Fully developed
Batch size: 230 Kg
Shelf life: 4 years
DMF/CEP availability: CEP/KDMF/J-MF
Pharmacopeia: EP
Treatment for Induced psychosis in patients with Parkinson disease
CAS No: [706782-28-7]
Status: Fully developed
Batch size: 24 Kg
Shelf life: 5 years
DMF/CEP availability: Under preparation
Treatment of Parkinson’s Disease
CAS No: [136236-52-7]
Status: Fully developed
Batch size: 16 Kg
Shelf life: 5 years
DMF/CEP availability: ASMF
Antipsychotic
CAS No: [106266-06-2]
Status: Fully developed
Batch size: 12 - 17 kg
Shelf life: 5 years
DMF/CEP availability: USDMF/ASMF
Pharmacopeia: USP
Treatment of Alzheimer’s Dementia
CAS No: [129101-54-8]
Status: Fully developed
Batch size: 400 Kg
Shelf life: 5 years
DMF/CEP availability: CEP
Pharmacopeia: EP
Treatment of Parkinson’s Disease
CAS No: [99755-59-6]
Status: Fully developed
Batch size: 16 - 38 kg
Shelf life: 5 years
DMF/CEP availability: USDMF/CEP
Pharmacopeia: USP/EP
Treatment of Urinary Incontinence
CAS No: [242478-38-2]
Status: Fully developed
Batch size: 190 Kg
Shelf life: 5 years
DMF/CEP availability: USDMF/CEP/T-DMF
Pharmacopeia: EP
Treatment of Erectile Disfunction and Pulmonary Arterial Hypertension
CAS No: [171596-29-5]
Status: Fully developed
Batch size: 25-32 kg & 120-228 kg
Shelf life: 5 years
DMF/CEP Availability: CEP/J-MF
Pharmacopeia: EP
Antihypertensive
CAS No: [144701-48-4]
Status: Fully developed
Batch size: 246 Kg
Shelf life: 5 years
DMF/CEP availability: CEP/J-MF
Pharmacopeia: EP
Treatment of Urinary Incontinence
CAS No: [124937-52-6]
Status: Fully developed
Batch size: 71 – 173 kg
Shelf life: 5 years
DMF/CEP availability: USDMF/CEP/KDMF/CN-DMF
Pharmacopeia: USP/EP
R&D Activities
Our R+D team has extensive experience in the field of developing chemical processes and purifying active ingredients. Work on synthesis is accompanied by the analytical development required to fully characterise our active pharmaceutical ingredients.
Our synthesis laboratories are fitted with state-of-the-art technology for process development. They have over 750 m2 of space for research, including a modern K-Lab, which works to GMP standards. Ferrer also has a pilot GMP plant suitable for all activities relating to scaling up our processes before marketing the end product.
Sustainable Development: Green Chemistry
We have ISO 14.001 certification, and we develop our processes in line with principles of sustainability.
From the initial development stages, our chemists work to avoid using hazardous or toxic substances and to minimise environmental emissions of contaminants.
Our facilities:
With a staff of over 178 people, our 18,000m2 state-of-the-art installations are located in Sant Cugat del Vallès, where our products are manufactured under strict European environmental and work safety regulations. The plant is approved by the US FDA, PMDA and EU, and our quality system and installations are governed by good manufacturing practices (GMP).
Would you like to get in touch?
SEND US AN E-MAIL
Additional contact details:
Carrer de Joan Buscallà, 10,
08173 Sant Cugat del Vallès (Barcelona)
Phone number: +34 935 044 200